Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives.

Moris D, Kontos M, Spartalis E, Fentiman IS.

Breast Care (Basel). 2016 Oct;11(5):339-344. Epub 2016 Oct 24. Review.

PMID:
27920627
2.

Use of acetaminophen in relation to the occurrence of cancer: a review of epidemiologic studies.

Weiss NS.

Cancer Causes Control. 2016 Dec;27(12):1411-1418. Epub 2016 Nov 10. Review.

3.

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study.

Dierssen-Sotos T, Gómez-Acebo I, de Pedro M, Pérez-Gómez B, Servitja S, Moreno V, Amiano P, Fernandez-Villa T, Barricarte A, Tardon A, Diaz-Santos M, Peiro-Perez R, Marcos-Gragera R, Lope V, Gracia-Lavedan E, Alonso MH, Michelena-Echeveste MJ, Garcia-Palomo A, Guevara M, Castaño-Vinyals G, Aragonés N, Kogevinas M, Pollán M, Llorca J.

BMC Cancer. 2016 Aug 20;16(1):660. doi: 10.1186/s12885-016-2692-4.

4.

Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women.

Bardia A, Keenan TE, Ebbert JO, Lazovich D, Wang AH, Vierkant RA, Olson JE, Vachon CM, Limburg PJ, Anderson KE, Cerhan JR.

Mayo Clin Proc. 2016 Jan;91(1):71-80. doi: 10.1016/j.mayocp.2015.10.018. Epub 2015 Dec 8.

5.

Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study.

Goedert JJ, Jones G, Hua X, Xu X, Yu G, Flores R, Falk RT, Gail MH, Shi J, Ravel J, Feigelson HS.

J Natl Cancer Inst. 2015 Jun 1;107(8). pii: djv147. doi: 10.1093/jnci/djv147. Print 2015 Aug.

6.

Impact of acetylsalicylic Acid on the clinicopathological characteristics and prognosis of patients with invasive breast cancer.

Sendur MA, Aksoy S, Ozdemir NY, Zengin N, Altundag K.

Breast Care (Basel). 2014 Apr;9(4):261-6. doi: 10.1159/000365952.

7.

Preventative therapies for healthy women at high risk of breast cancer.

Sestak I.

Cancer Manag Res. 2014 Oct 17;6:423-30. doi: 10.2147/CMAR.S55219. eCollection 2014. Review.

8.

Cyclooxygenase-2 and the inflammogenesis of breast cancer.

Harris RE, Casto BC, Harris ZM.

World J Clin Oncol. 2014 Oct 10;5(4):677-92. doi: 10.5306/wjco.v5.i4.677. Review.

9.

Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence.

Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE.

J Clin Oncol. 2012 Oct 1;30(28):3468-77. Epub 2012 Aug 27.

10.

Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Reader J, Holt D, Fulton A.

Cancer Metastasis Rev. 2011 Dec;30(3-4):449-63. doi: 10.1007/s10555-011-9303-2. Review.

11.

Regular aspirin use and breast cancer risk in US Black women.

Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L.

Cancer Causes Control. 2011 Nov;22(11):1553-61. doi: 10.1007/s10552-011-9832-6. Epub 2011 Aug 30.

12.

Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies.

Vinogradova Y, Coupland C, Hippisley-Cox J.

Br J Cancer. 2011 Jul 26;105(3):452-9. doi: 10.1038/bjc.2011.252. Epub 2011 Jul 12.

13.

Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.

Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR.

Breast Cancer Res Treat. 2011 Feb;126(1):149-55. doi: 10.1007/s10549-010-1074-x. Epub 2010 Jul 29.

14.

Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study.

Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Trevisan M, Shields PG, Freudenheim JL.

Cancer Causes Control. 2010 Sep;21(9):1503-12. doi: 10.1007/s10552-010-9579-5. Epub 2010 May 25.

15.

Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.

Cronin-Fenton DP, Pedersen L, Lash TL, Friis S, Baron JA, Sørensen HT.

Breast Cancer Res. 2010;12(2):R15. doi: 10.1186/bcr2482. Epub 2010 Mar 1.

16.

The case for developing publicly-accessible datasets for health services research in the Middle East and North Africa (MENA) region.

Saleh SS, Alameddine MS, El-Jardali F.

BMC Health Serv Res. 2009 Oct 29;9:197. doi: 10.1186/1472-6963-9-197.

17.

Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II.

Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE.

Arch Intern Med. 2009 Jan 26;169(2):115-21; discussion 121. doi: 10.1001/archinternmed.2008.537.

18.

Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.

Brown PH, Subbaramaiah K, Salmon AP, Baker R, Newman RA, Yang P, Zhou XK, Bissonnette RP, Dannenberg AJ, Howe LR.

Cancer Prev Res (Phila). 2008 Aug;1(3):208-14. doi: 10.1158/1940-6207.CAPR-08-0021.

19.

Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs.

Howe LR, Lippman SM.

J Natl Cancer Inst. 2008 Oct 15;100(20):1420-3. doi: 10.1093/jnci/djn347. Epub 2008 Oct 7. No abstract available.

20.

Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women.

Terry MB, Buist DS, Trentham-Dietz A, James-Todd TM, Liao Y.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1088-95. doi: 10.1158/1055-9965.EPI-07-2836.

Supplemental Content

Support Center